GlassScriptPhysician profile
Mohammed Al-Dalli
NPI 1205960630
$9,961.62
in general payments reported to CMS, 2019-2025
53 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,584 · 2020: $1,297 · 2021: $1,534 · 2022: $1,406 · 2023: $1,666 · 2024: $1,392 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,112.82 | 2019-2025 | Otezla, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $976.50 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Novo Nordisk INC | $866.11 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $676.68 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $589.30 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $542.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $519.25 | 2019-2023 | Ubrelvy, Synthroid |
| Esperion Therapeutics, INC. | $508.75 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $493.91 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $485.38 | 2019-2022 | |
| Lilly USA, LLC | $382.08 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $350.31 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Kowa Pharmaceuticals America, INC. | $307.77 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amarin Pharma, INC. | $306.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.30 | 2019-2024 | Jardiance |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Al-Dalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.